0.00Open18.00Pre Close0 Volume0 Open Interest57.00Strike Price0.00Turnover7380.18%IV-3.97%PremiumNov 22, 2024Expiry Date21.10Intrinsic Value100Multiplier-5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9648Delta0.0076Gamma4.34Leverage Ratio-284.6150Theta0.0000Rho4.19Eff Leverage0.0001Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet